Bide Pharmatech Co

Bide Pharmatech Co EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Bide Pharmatech Co (688073.SS) as of Oct 30, 2026 is 193.13. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 34.03 — a change of 467.57% (higher).

EV/OCF

193.13

YoY

467.57%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Bide Pharmatech Co is 2025 193.13 . EV/OCF (Enterprise Value to Operating Cash Flow) of Bide Pharmatech Co was 2024 34.03 . It decreases by 467.57% higher compared to the previous year.

The Bide Pharmatech Co EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2019
1,802.52 CNY
Jan 1, 2020
1,477.89 CNY
Jan 1, 2021
-83.03 CNY
Jan 1, 2022
180.34 CNY
Jan 1, 2023
-93.87 CNY
Jan 1, 2024
34.03 CNY
Jan 1, 2025
193.13 CNY
The Bide Pharmatech Co EV/OCF history
YEAREV/OCFYoY
193.13+467.57%
34.03-136.25%
-93.87-152.05%
180.34-317.21%
-83.03-105.62%
1,477.89-18.01%
1,802.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bide Pharmatech Co Stock analysis

What does Bide Pharmatech Co do? Bide Pharmatech Co., Ltd. generates revenue through the research, development, design, production, and sales of pharmaceutical molecular building blocks and scientific reagents. The company's primary products serve drug target discovery, seed compound screening, lead compound discovery, synthesis, and optimization processes. Key markets include Asia Pacific, India, Europe, and the United States, where the firm's offerings are utilized by pharmaceutical companies and research institutions. The business model relies on direct sales of its specialized chemical products to these industry segments. The firm's main focus is on developing molecular building blocks for drug development, with products specifically designed for early-stage pharmaceutical research. These building blocks are essential for creating and refining potential drug candidates. The company's operations span multiple global regions, targeting pharmaceutical manufacturers and academic research organizations that require high-quality chemical compounds for their development pipelines. Bide Pharmatech's revenue streams are derived from the sale of its proprietary molecular building blocks and reagents, which are integral to pharmaceutical R&D processes. The company serves clients in the pharmaceutical sector across Asia Pacific, India, Europe, and the United States, delivering products that support critical stages of drug discovery and development. Bide Pharmatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bide Pharmatech Co stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Bide Pharmatech Co is 193.13 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Bide Pharmatech Co changed from 34.03 to 193.13, representing a 467.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Bide Pharmatech Co since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Bide Pharmatech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bide Pharmatech Co

All Key Metrics — Bide Pharmatech Co